Loss of SOX9 expression is associated with PSA recurrence in ERG-positive and PTEN deleted prostate cancers

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Burdelski, Christoph ^a   Bujupi, Erzen ^b   Tsourlakis, Maria Christina ^a   Hube Magg, Claudia ^a   Kluth, Martina ^a   Melling, Nathaniel ^a   Lebok, Patrick ^a   Minner, Sarah ^a   Koop, Christina ^a   Graefen, Markus ^a   Heinzer, Hans ^a   Wittmer, Corinna ^a   Sauter, Guido ^a   Wilczak, Waldemar ^a   Simon, Ronald ^a   Schlomm, Thorsten ^a   Steurer, Stefan ^a   Krech, Till ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b St Franziskus Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR SOX9; ERG PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; SOX9 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; GENE DOSAGE; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; TUMOR PROMOTION; BLOOD; GENETICS; PATHOLOGY; PROSTATE TUMOR; RECURRENT DISEASE;

HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECURRENCE; SOX9 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSCRIPTIONAL REGULATOR ERG;

EID: 84932607546     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128525     Document Type: Article

References (38)

1. Jemal A, Ward E, Wu X, Martin HJ, McLaughlin CC, Thun MJ (2005) Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev 14: 590-595. PMID: 15767335
2. Lefebvre V, Dumitriu B, Penzo-Mendez A, Han Y, Pallavi B (2007) Control of cell fate and differentiation by Sry-related high-mobility-group box (Sox) transcription factors. Int J Biochem Cell Biol 39: 2195-2214. PMID: 17625949
3. Koopman P (2005) Sex determination: a tale of two Sox genes. Trends Genet 21: 367-370. PMID: 15949865
4. Bi W, Deng JM, Zhang Z, Behringer RR, de Crombrugghe B (1999) Sox9 is required for cartilage formation. Nat Genet 22: 85-89. PMID: 10319868
5. Stolt CC, Lommes P, Sock E, Chaboissier MC, Schedl A, Wegner M (2003) The Sox9 transcription factor determines glial fate choice in the developing spinal cord. Genes Dev 17: 1677-1689. PMID: 12842915
6. Akiyama H, Chaboissier MC, Behringer RR, Rowitch DH, Schedl A, Epstein JA, et al. (2004) Essential role of Sox9 in the pathway that controls formation of cardiac valves and septa. Proc Natl Acad Sci U S A 101: 6502-6507. PMID: 15096597
7. Taylor KM, Labonne C (2005) SoxE factors function equivalently during neural crest and inner ear development and their activity is regulated by SUMOylation. Dev Cell 9: 593-603. PMID: 16256735
8. Vidal VP, Chaboissier MC, Lutzkendorf S, Cotsarelis G, Mill P, Hui CC, et al. (2005) Sox9 is essential for outer root sheath differentiation and the formation of the hair stem cell compartment. Curr Biol 15: 1340-1351. PMID: 16085486
9. Seymour PA, Freude KK, Tran MN, Mayes EE, Jensen J, Kist R, et al. (2007) SOX9 is required for maintenance of the pancreatic progenitor cell pool. Proc Natl Acad Sci U S A 104: 1865-1870. PMID: 17267606
10. Schaeffer EM, Marchionni L, Huang Z, Simons B, Blackman A, Yu W, et al. (2008) Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene 27: 7180-7191. doi: 10.1038/onc.2008.327 PMID: 18794802
11. Wang H, McKnight NC, Zhang T, Lu ML, Balk SP, Yuan X (2007) SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Cancer Res 67: 528-536. PMID: 17234760
12. Thomsen MK, Butler CM, Shen MM, Swain A (2008) Sox9 is required for prostate development. Dev Biol 316: 302-311. doi: 10.1016/j.ydbio.2008.01.030 PMID: 18325490
13. Wang H, Leav I, Ibaragi S, Wegner M, Hu GF, Lu ML, et al. (2008) SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res 68: 1625-1630. doi: 10.1158/0008-5472.CAN-07-5915 PMID: 18339840
14. Thomsen MK, Ambroisine L, Wynn S, Cheah KS, Foster CS, Fisher G, et al. (2010) SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res 70: 979-987. doi: 10.1158/0008-5472.CAN-09-2370 PMID: 20103652
15. Zhong W-d, Qin G-q, Dai Q-s, Han Z-d, Chen S-m, Ling X-h, et al. (2012) SOXs in human prostate cancer: implication as progression and prognosis factors. BMC cancer 12: 248. doi: 10.1186/1471-2407:12-248 PMID: 22703285
16. Wang G, Lunardi A, Zhang J, Chen Z, Ala U, Webster KA, et al. (2013) Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat Genet 45: 739-746. doi: 10.1038/ng.2654 PMID: 23727861
17. Qin GQ, He HC, Han ZD, Liang YX, Yang SB, Huang YQ, et al. (2014) Combined overexpression of HIVEP3 and SOX9 predicts unfavorable biochemical recurrence-free survival in patients with prostate cancer. Onco Targets Ther 7: 137-146. doi: 10.2147/OTT.S55432 PMID: 24493929
18. Eble JN, Sauter G, Epstein J, Sesterhenn I (2004) Pathology and genetics of tumours of the urinary system and male genital organs: International Agency for Research on Cancer. 359 p.
19. Schlomm T, Iwers L, Kirstein P, Jessen B, Kollermann J, Minner S, et al. (2008) Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 21: 1371-1378. doi: 10.1038/modpathol.2008.104 PMID: 18552821
20. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847. PMID: 9662379
21. Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, et al. (2011) ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 17: 5878-5888. doi: 10.1158/1078-0432.CCR-11-1251 PMID: 21791629
22. Burkhardt L, Fuchs S, Krohn A, Masser S, Mader M, Kluth M, et al. (2013) CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res 73: 2795-2805. doi: 10.1158/0008-5472.CAN-12-1342 PMID: 23492366
23. Kluth M, Hesse J, Heinl A, Krohn A, Steurer S, Sirma H, et al. (2013) Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol.
24. Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, et al. (2012) Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol 181: 401-412. doi: 10.1016/j.ajpath.2012.04.026 PMID: 22705054
25. Krohn A, Seidel A, Burkhardt L, Bachmann F, Mader M, Grupp K, et al. (2013) Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion: positive prostate cancers. J Pathol 231: 130-141. doi: 10.1002/path.4223 PMID: 23794398
26. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, et al. (2011) The genomic complexity of primary human prostate cancer. Nature 470: 214-220. doi: 10.1038/nature09744 PMID: 21307934
27. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22. doi: 10.1016/j.ccr.2010.05.026 PMID: 20579941
28. Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, et al. (2007) Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 67: 8504-8510. PMID: 17875689
29. Epstein JI, Feng Z, Trock BJ, Pierorazio PM (2012) Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 61: 1019-1024. doi: 10.1016/j.eururo.2012.01.050 PMID: 22336380
30. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648. PMID: 16254181
31. Cai C, Wang H, He HH, Chen S, He L, Ma F, et al. (2013) ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest 123: 1109-1122. doi: 10.1172/JCI66666 PMID: 23426182
32. Chen Z, Trotman LC, Shaffer D, Lin H- K, Dotan ZA, Niki M, et al. (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436: 725-730. PMID: 16079851
33. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P, et al. (2010) FZD4 as a mediator of ERG oncogene: induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 70: 6735-6745. doi: 10.1158/0008-5472.CAN-10-0244 PMID: 20713528
34. Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI, et al. (2006) TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 66: 10242-10246. PMID: 17079440
35. Tsuda M, Takahashi S, Takahashi Y, Asahara H (2003) Transcriptional co-activators CREB-binding protein and p300 regulate chondrocyte-specific gene expression via association with Sox9. J Biol Chem 278: 27224-27229. PMID: 12732631
36. Ring A, Kim YM, Kahn M (2014) Wnt/catenin signaling in adult stem cell physiology and disease. Stem Cell Rev 10: 512-525. doi: 10.1007/s12015-014-9515-2 PMID: 24825509
37. Drivdahl R, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, Plymate SR (2004) Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9. Oncogene 23: 4584-4593. PMID: 15077158
38. Brase JC, Johannes M, Mannsperger H, Falth M, Metzger J, Kacprzyk LA, et al. (2011) TMPRSS2: ERG-specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer 11: 507. doi: 10.1186/1471-2407-11-507 PMID: 22142399